Tucatinib (ONT-380)

DRUG2 trials

Sponsors

Seagen Inc., Institut Curie

Conditions

HER2 Positive Breast CancersMetastatic Breast Cancer ( HER2 Negative)Unresectable Breast Cancer

Phase 1

A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer

CompletedNCT01983501

Seagen Inc.HER2 Positive Breast Cancers

Start: 2014-02-28End: 2020-09-03Updated: 2020-09-21

Phase 2

Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer

RecruitingNCT07193394

Institut CurieMetastatic Breast Cancer ( HER2 Negative), Unresectable Breast Cancer

Start: 2026-01-31End: 2029-06-08Target: 20Updated: 2026-02-23

Related Papers

Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal Cancer

Clinical Pharmacokinetics2024-10-012 citations

Abstract PS10-08: Tucatinib potentiates the activity of the antibody-drug conjugate T-DM1 in preclinical models of HER2-positive breast cancer

Cancer Research2021-02-155 citations

Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced <i>ERBB2/HER2</i>-Positive Metastatic Breast Cancer

JAMA Oncology2018-06-28161 citations

Clinical benefit of tucatinib after isolated brain progression: A retrospective pooled analysis of tucatinib phase 1b studies in HER2+ breast cancer.

Journal of Clinical Oncology2018-05-207 citations

Abstract P4-14-19: ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets)

Cancer Research2016-02-157 citations

ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets).

Journal of Clinical Oncology2015-05-2011 citations

A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with ado-trastuzumab emtansine (T-DM1), in HER2+ metastatic breast cancer (MBC).

Journal of Clinical Oncology2014-05-203 citations